SYNERGY(SZ:300636)2023-10-25 16:00Financial Performance - The company's operating revenue for Q3 2023 was ¥177,907,849.05, a decrease of 7.48% compared to the same period last year[5] - The net profit attributable to shareholders for Q3 2023 was ¥21,622,335.15, down 32.11% year-on-year[5] - The basic earnings per share for Q3 2023 was ¥0.0522, a decline of 45.23% compared to the previous year[5] - Total operating revenue for the third quarter reached CNY 559,661,869.75, an increase of 5.5% compared to CNY 528,274,967.87 in the same period last year[21] - Net profit attributable to the parent company was CNY 78,653,167.86, representing a growth of 5.8% from CNY 74,486,244.48 in the previous year[22] Assets and Liabilities - Total assets as of September 30, 2023, reached ¥3,143,628,096.89, representing a 39.17% increase from the end of the previous year[5] - The company's total equity attributable to shareholders reached CNY 2,190,980,696.85, compared to CNY 1,319,668,598.10 in the previous year, reflecting a growth of 66%[22] - Total liabilities as of September 30, 2023, were CNY 952,647,400.04, a slight increase from CNY 939,186,880.03 at the beginning of the year[19] - The equity attributable to owners increased to CNY 1,711,980,696.92 from CNY 1,051,190,543.29, representing a growth of approximately 62.8%[19] Cash Flow - Cash flow from operating activities for the year-to-date period was ¥105,729,138.58, down 25.22% compared to the previous year[5] - The company reported a significant increase in cash and cash equivalents, rising by 190.22% to ¥412,014,668.40 due to a specific share issuance[10] - Net cash flow from investment activities improved by 148.19% to -CNY 701,445,884.57 from -CNY 282,627,003.36, primarily due to increased purchases of large bank deposits[11] - Net cash flow from financing activities skyrocketed by 1419.17% to CNY 884,060,327.09 from CNY 58,193,647.52, mainly due to the issuance of shares and increased borrowings[11] - The total cash inflow from financing activities was 1,522,814,687.43 CNY, significantly up from 354,462,270.40 CNY year-over-year[24] Expenses - Tax and additional fees increased by 58.28% to CNY 2,802,759.71 compared to CNY 1,770,787.53 in the same period last year, primarily due to an increase in property tax[11] - Sales expenses rose by 41.43% to CNY 17,560,749.16 from CNY 12,416,748.36, mainly due to increased employee compensation and product registration certification fees[11] - Management expenses increased by 32.33% to CNY 27,957,757.43 from CNY 21,127,421.42, attributed to higher equity incentive costs[11] - Financial expenses decreased by 277.69% to -CNY 4,044,746.02 from CNY 2,276,276.22, mainly due to increased interest income and foreign exchange gains[11] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 14,778[12] - The largest shareholder, Pang Zhengwei, holds 15.60% of shares, amounting to 66,009,954 shares, with 15,750,000 shares pledged[12] Company Developments - The company completed the first phase of its new plant project, which includes four workshops that have begun trial production[16] - Jiangxi Tonghe Pharmaceutical issued 72,926,162 new shares at a price of CNY 10.97 per share, raising significant capital for expansion[17] - The company has ongoing projects for the expansion and upgrade of its second plant, with construction of new facilities having commenced in July 2022[16] Audit and Reporting - The company did not undergo an audit for the third quarter report[25] - The report was released on October 25, 2023, indicating timely communication of financial performance[25]